had "inappropriately awarded research funding" to a senior clinician at a British hospital, directly resulting in the hospital adopting a protocol which was subsequently abandoned less than three years later "because of poor outcomes". This report also reprimanded Astellas for failing to provide sufficient and timely information to investigators. In April 2019, Astellas agreed to pay the United States Department of Justice $100 million to resolve allegations that it had conspired to offer kickbacks via Medicare copay foundations. Business Astellas' franchise areas are oncology, urology, immunology (transplantation), cardiology, and infectious disease. Priority areas for R&D are infectious diseases, diabetes, gastrointestinal diseases, oncology, and diseases of the central nervous system. Recently noted, Astellas Venture Management has funded Oncorus, which recently raised $79.5 million in a series B financing round to move two oncolytic viruses through development. Products Some of the key products produced by Astellas include: Adenocard (adenosine injection) – Pharmacologic stress agent for myocardial perfusion scan Adenoscan (adenosine injection) – Pharmacologic stress agent for myocardial perfusion scan AmBisome (amphotericin B) – Anti-fungal – marketed with Gilead Sciences. Amevive (alefacept) – plaque psoriasis Astagraf XL (tacrolimus) – Prevention of post-transplant organ rejection Cresemba (isavuconazole) – Anti-fungal Evrenzo (roxadustat) - Anemia due to chronic kidney disease (CKD) Flomax (tamsulosin hydrochloride) – Benign prostatic hyperplasia (BPH) Flomax MR capsules were discontinued in 2005, replaced by Flomaxtra XL, containing the same active ingredient Lexiscan (regadenoson injection) – Pharmacologic stress agent for myocardial perfusion scan Macugen (pegaptanib sodium) – Anti-angiogenic – marketed with Gilead Sciences in the US and Pfizer Outside of US. Mycamine (micafungin sodium) – Anti-fungal Myrbetriq (mirabegron) – Overactive bladder (OAB) – US only marketed by Pfizer Outside of US. Padcev (enfortumab vedotin) - Bladder cancer Prograf (tacrolimus) – Prevention of post-transplant organ rejection Protopic (tacrolimus ointment) – Atopic dermatitis (eczema) Symoron (methadone HCL) – Opioid replacement therapy Tarceva (erlotinib) – Non-small cell lung cancer and pancreatic cancer – marketed with Hoffmann-La Roche (Genentech). Vaprisol (conivaptan) – Hyponatremia Vesicare (solifenacin succinate) – Overactive bladder (OAB) Vibativ (telavancin) – bactericidal lipoglycopeptide – marketed with Theravance. Xospata (gilteritinib) – AXL receptor tyrosine kinase Xtandi (enzalutamide) – Prostate cancer – marketed with Pfizer. Distribution agreements In 2007, the company narrowed UK distribution of Advagraf and Prograf to a sole distributor, UniChem, in reaction to pharmacist complaints about drug availability from wholesale sources. This narrow distribution was revised to three firms in 2010, covering all of